Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.

Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations, known as Miaoshou Doctor. The company's latest round was led jointly by Sequoia Capital China and Tencent.